Evogene Ltd. (EVGN) Stock: Price, Forecast & Analyst Target
Evogene Ltd. (EVGN) — price $0.3645 (+0.11%), as of the Oct 26, 2026 trading session; market cap $3.14M.
Educational signal · not a buy or sell recommendation · How to read this
Evogene Ltd. · EVGN
Evogene Ltd. is a computational biology company focused on product discovery and development across human health and agriculture. The company leverages its Computational Predictive Biology (CPB) platform to develop products based on microbes, small molecules, and genetic elements.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.3645 | |
| Change on the day | +0.11% | |
| 52-week range | $0.3452 – $1.33 | |
| Market capitalisation | $3.14M | |
| Price / earnings (trailing) | -3.41 | |
| Shares traded on the day | 7.8K |
Price & events
Other perspectives
Council score for Evogene (EVGN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the EVGN film — every key number, told as a short cinematic story
~2 min · open the film
What is Evogene (EVGN), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Evogene Ltd. (EVGN) is the company analyzed here. It employs 52 people and is led by Ofer Haviv. In Q2 FY2026 it reported revenue of $347,000 and net income of -$2M. The market values it at $3.14M.
What do the latest results show for Evogene (EVGN)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $347,000. Against analyst estimates the company has EPS beat 4 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $347,000 | -$2M | -$0.14 (diluted) |
| Q1 FY2026 | $334,000 | -$6M | -$0.60 (diluted) |
| Q4 FY2025 | $314,000 | -$5M | -$0.61 (diluted) |
| Q3 FY2025 | $312,000 | $4M | $0.44 (diluted) |
What are the financial strengths and risks for Evogene (EVGN)?
Short answer
The distress and quality screens read Altman Z -32.49 · Piotroski F 1. Trailing ratios: ROA -68.2% · current ratio 3.57 · earnings yield -133.1%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -32.49 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Evogene (EVGN)?
Short answer · as of
Current published price targets run low $2.15 · high $2.15 · consensus $2.15 · median $2.15 against a quoted price of $0.3645 (as of Oct 26, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $2.15 – $2.15
- Consensus target
- $2.15
- Median target
- $2.15
Consensus record · Captured .
Measured against a quoted price of $0.3645 (as of Oct 26, 2026).
Common Questions About EVGN
These answers are editorial: 1 of these 8 answers is drawn from the EVGN research dossier (written Jun 1, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is EVGN a good stock to buy?
Stock Expert AI does not rate EVGN buy, sell or hold. Evogene Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the EVGN stock price today?
The last price recorded on this page for Evogene Ltd. (EVGN) is $0.3645, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the EVGN price target?
The analyst consensus price target for Evogene Ltd. (EVGN) is $2.15 (range $2.15 to $2.15, median $2.15), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about EVGN stock?
Analyst coverage of Evogene Ltd. (EVGN) is limited, reflecting its small market capitalization and speculative nature. Key valuation metrics are difficult to assess due to the company's negative profit margin.
What are the key factors to evaluate for EVGN?
Evaluate EVGN on fundamentals, analyst consensus, and risk factors. Analysts target $2.15 (+490%). The company can further expand its geographic footprint by targeting high-growth markets in Asia and Latin America. Not financial advice.
How frequently does EVGN data refresh on this page?
EVGN's price is the last quote we recorded, from the Oct 26, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven EVGN's recent stock price performance?
Evogene Ltd. (EVGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Computational Predictive Biology (CPB) platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EVGN overvalued or undervalued right now?
Evogene Ltd. (EVGN) is loss-making, so its trailing P/E is negative (-3.41x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $2.15 (+490%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (19 figures)
The 19 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 13 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.3645 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T15:44:46.687Z. | |
px.change | Change on the day | +0.11% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $3.14M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T15:26:03.000Z. Captured from FMP at 2026-10-26T15:44:45.579Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.0004 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | -3.41 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 7.8K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $347,000 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$2M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $2.15 · high $2.15 · consensus $2.15 · median $2.15 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $2.15 – $2.15 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $2.15 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $2.15 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.3452 – $1.33 | UNRECORDED | Stored company-profile observation — Captured 2026-10-22 | |
id.employees | Employees | 52 | UNRECORDED | Stored company-profile observation — Captured 2026-10-22 | |
id.ceo | Chief executive | Ofer Haviv | UNRECORDED | Stored company-profile observation — Captured 2026-10-22 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-07 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -32.49 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROA -68.2% · current ratio 3.57 · earnings yield -133.1% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.